MedTrace Logo

MA-CRC-II-016 SHR-1811

NCT07355764 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-01-21

No results posted yet for this study

Summary

A randomized, controlled, multicenter clinical study of SHR-A1811 combined with bevacizumab for the second-line treatment of metastatic colorectal cancer

Conditions

  • mCRC
  • HER2
  • Targeted Therapy
  • Antibody-drug Conjugates

Interventions

DRUG

SHR-A1811 & Bevacizumab injection

HER2 ADC

DRUG

Chemotherapeutic Combinations

FOLFIRI+BEV

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-30
Primary Completion
2028-01-30
Completion
2028-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07355764 on ClinicalTrials.gov